Mirum Pharmaceuticals, Inc. (MIRM) Stock

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is led by CEO Christopher Peetz, employs 418 people, headquartered in Foster City, US, publicly traded since 2019.

Mirum Pharmaceuticals, Inc. (MIRM) stock trades at $80.39 with a market capitalization of $5.22B. The stock is valued at a negative price-to-earnings (P/E) ratio of -5.50, reflecting a net loss over the last twelve months, a negative price-to-book of -487.32, reflecting negative shareholders' equity, price-to-sales of 8.42. Over the past 52 weeks the stock has ranged between $63.23 and $130.00, and currently trades 38.2% below its 52-week high.

On profitability, Mirum Pharmaceuticals, Inc. generates a return on equity (ROE) of -410.20% (not meaningful, as shareholders' equity is negative), return on capital employed of -13.09%, an operating margin of -39.51%, a net profit margin of -139.18%.

Mirum Pharmaceuticals, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Mirum Pharmaceuticals, Inc. reported revenue of $0 rising to $521.0M. Compounded, revenue has grown —% a year over five years, 89.1% over three, 54.6% over the last twelve months. Net profit fell to $-23.0M.

The most recent net margin is -139.18%. On a trailing twelve-month basis to Jun '26, revenue is $618.0M and net profit $-860.0M.

Borrowings stand at $319.0M, cash from operations was $56.0M in the latest year, positive in 2 of the last 8.

Return on equity has averaged -55.5% over five years, and was -7.3% in the most recent year.

The share price itself has compounded at 43.7% a year over five years, 60.1% over three, 134.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Mirum Pharmaceuticals, Inc. (MIRM) — frequently asked questions